The settlement removes patent litigation overhang and provides clarity on generic entry timing (Sept 2030). Monitor FTC/DOJ review outcome and any potential impact on Jelmyto revenue trajectory. The 4+ year runway to generic entry is a modest positive for Jelmyto's commercial outlook.
Price Chart
Executive Summary
UroGen Pharma settled patent litigation with Teva over Jelmyto (mitomycin) for pyelocalyceal solution. Under the settlement, UroGen grants Teva a non-exclusive license to sell a generic version beginning September 15, 2030, if FDA-approved. The agreement resolves all ongoing patent litigation in the U.S. District Court for the District of Delaware and is subject to FTC/DOJ review.
Key Facts
- UroGen entered a settlement and license agreement with Teva resolving patent litigation over Jelmyto (mitomycin) for pyelocalyceal solution.
- Teva will receive a non-exclusive license to sell its generic version of Jelmyto beginning September 15, 2030, if FDA-approved.
- All ongoing patent litigation between the parties in the U.S. District Court for the District of Delaware will be terminated.
- The agreement is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice.
- No financial terms of the settlement were disclosed in the filing.
Financial Impact
No financial terms disclosed. The settlement removes litigation uncertainty and establishes a generic entry date of September 15, 2030, which is approximately 4+ years from now.
Risk Factors
- FTC or DOJ could challenge or modify the settlement terms.
- Earlier generic entry if certain limited customary circumstances occur.
- No financial terms disclosed — potential undisclosed royalty or payment structure could alter the economic impact.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-019102 |
| Document: 0001437749-26-019102-index-headers.html | 0001437749-26-019102 |
| Document: 0001437749-26-019102-index.html | 0001437749-26-019102 |
| Document: 0001437749-26-019102.txt | 0001437749-26-019102 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | Insider Cluster | $45.00 $43.04 | ▼ −4.36% | ▼ −4.02% | $41.40 (−8.00%) |
Aug 20, 2026 6w ago | 8-K | $46.80 $45.50 | ▼ −2.78% | ▼ −3.89% | $41.40 (−11.54%) |
Aug 5, 2026 8w ago | 8-K | $46.43 $49.00 | ▲ +5.54% | ▲ +5.18% | $41.40 (−10.83%) |
Jun 23, 2026 14w ago | 8-K | $35.42 $37.94 | ▲ +7.11% | ▲ +5.41% | $41.40 (+16.88%) |
Jun 2, 2026 17w ago | 8-K | $26.54 $28.18 | ▲ +6.18% | ▲ +9.14% | $41.40 (+55.99%) |
May 6, 2026 21w ago | Press Release | $26.25 $29.80 | ▲ +13.52% | ▲ +12.39% | $41.40 (+57.71%) |
Apr 29, 2026 22w ago | Press Release | $23.34 $23.83 | ▼ −2.10% | ▲ +1.01% | $41.40 (−77.38%) |
Mar 2, 2026 30w ago | Press Release | $19.02 $19.91 | ▲ +4.68% | ▲ +5.89% | $41.40 (+117.67%) |
Mar 2, 2026 30w ago | Press Release | $19.02 $19.91 | ▲ +4.68% | ▲ +5.89% | $41.40 (+117.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access